Intergenically Spliced Chimeric RNAs in Cancer

Trends in Cancer

Volumn 2, Issue 9, 2016, Pages 475-484

  Jia, Yuemeng ^a   Xie, Zhongqiu ^a   Li, Hui ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

chimeric RNA; cis SAGe; fusion; intergenic splicing; trans splicing

Indexed keywords

BIOLOGICAL MARKER; DNA; INTERGENICALLY SPLICED CHIMERIC RNA; RNA; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER THERAPY; CHROMOSOME REARRANGEMENT; GENE FUSION; HUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; TRANS SPLICING; GENETICS; NEOPLASM;

BIOMARKERS, TUMOR; GENE FUSION; HUMANS; NEOPLASMS; RNA SPLICING;

EID: 84989961175     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.07.006     Document Type: Review

References (83)

1. 1 Rabbitts, T.H., Chromosomal translocations in human cancer. Nature 372 (1994), 143–149.
2. 2 Rowley, J.D., A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973), 290–293.
3. 3 Heim, S., Mitelman, F., Molecular screening for new fusion genes in cancer. Nature Genetics 40 (2008), 685–686.
4. 4 Downing, J.R., et al. Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am. J. Pathol. 146 (1995), 626–634.
5. 5 Rowley, J.D., The role of chromosome translocations in leukemogenesis. Seminars in Hematol. 36 (1999), 59–72.
6. 6 Tomlins, S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005), 644–648.
7. 7 Kowarz, E., et al. Premature transcript termination, trans-splicing and DNA repair: a vicious path to cancer. Am. J. Blood res. 1 (2011), 1–12.
8. 8 Druker, B.J., et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001), 1031–1037.
9. 9 Shaw, A.T., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12 (2011), 1004–1012.
10. 10 Li, H., et al. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321 (2008), 1357–1361.
11. 11 Chase, A., et al. TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica 95 (2010), 20–26.
12. 12 Yuan, H., et al. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process. Cancer Discov. 3 (2013), 1394–1403.
13. 13 Wu, C.S., et al. Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency. Genome Res. 24 (2014), 25–36.
14. 14 Relaix, F., et al. The transcriptional activator PAX3–FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17 (2003), 2950–2965.
15. 15 Zhang, Y., et al. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov. 2 (2012), 598–607.
16. 16 Velusamy, T., et al. Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. U.S.A. 110 (2013), 3035–3040.
17. 17 Babiceanu, M., et al. Recurrent chimeric fusion RNAs in non-cancer tissues and cells. Nucleic Acids Res. 44 (2016), 2859–2872.
18. 18 Soda, M., et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
19. 19 Li, Y., et al. Clinical significance of EML4–ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PloS ONE, 8, 2013, e52093.
20. 20 Wechsler, D.S., et al. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. Genes, Chromosomes & Cancer 36 (2003), 26–36.
21. 21 Morerio, C., et al. Inversion (11)(p15q22) with NUP98–DDX10 fusion gene in pediatric acute myeloid leukemia. Cancer Genet. Cytogenet. 171 (2006), 122–125.
22. 22 Haferlach, C., et al. AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 24 (2010), 1065–1069.
23. 23 Hermans, K.G., et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66 (2006), 10658–10663.
24. 24 Perner, D., et al. Association between sun-exposure, smoking behaviour and plasma antioxidant levels with the different manifestation of skin ageing signs between Japanese and German women–a pilot study. J. Dermatol. Sci. 62 (2011), 138–140.
25. 25 Santo, E.E., et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 31 (2012), 1571–1581.
26. 26 Jividen, K., Li, H., Chimeric RNAs generated by intergenic splicing in normal and cancer cells. Genes Chromosomes Cancer 53 (2014), 963–971.
27. 27 Wang, K., et al. RBM6-RBM5 transcription-induced chimeras are differentially expressed in tumours. BMC Genomics, 8, 2007, 348.
28. 28 Parra, G., et al. Tandem chimerism as a means to increase protein complexity in the human genome. Genome Res. 16 (2006), 37–44.
29. 29 Denoeud, F., et al. Prominent use of distal 5’ transcription start sites and discovery of a large number of additional exons in ENCODE regions. Genome Res. 17 (2007), 746–759.
30. 30 Siepel, A., et al. Targeted discovery of novel human exons by comparative genomics. Genome Res. 17 (2007), 1763–1773.
31. 31 Kannan, K., et al. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc. Nat. Acad. Sci. U.S.A. 108 (2011), 9172–9177.
32. 32 Nacu, S., et al. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med. Genomics, 4, 2011, 11.
33. 33 Hernandez-Torres, F., et al. Intron retention and transcript chimerism conserved across mammals: Ly6g5b and Csnk2b–Ly6g5b as examples. BMC Genomics, 14, 2013, 199.
34. 34 Akiva, P., et al. Transcription-mediated gene fusion in the human genome. Genome Res. 16 (2006), 30–36.
35. 35 Qin, F., et al. Discovery of CTCF-sensitive cis-spliced fusion RNAs between adjacent genes in human prostate cells. PLoS Genet., 11, 2015, e1005001.
36. 36 Murphy, L.C., et al. Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res. Treat. 26 (1993), 149–161.
37. 37 Pink, J.J., et al. Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line. Br. J. Cancer 75 (1997), 17–27.
38. 38 Gingeras, T.R., Implications of chimaeric non-co-linear transcripts. Nature 461 (2009), 206–211.
39. 39 Sutton, R.E., Boothroyd, J.C., Evidence for trans splicing in trypanosomes. Cell 47 (1986), 527–535.
40. 40 Krause, M., Hirsh, D., A trans-spliced leader sequence on actin mRNA in C. elegans. Cell 49 (1987), 753–761.
41. 41 Nilsen, T.W., Evolutionary origin of SL-addition trans-splicing: still an enigma. Trends Genet. 17 (2001), 678–680.
42. 42 Lasda, E.L., Blumenthal, T., Trans-splicing. Wiley interdisciplinary reviews. RNA 2 (2011), 417–434.
43. 43 Hastings, K.E., SL trans-splicing: easy come or easy go?. Trends Genet. 21 (2005), 240–247.
44. 44 Finta, C., Zaphiropoulos, P.G., Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. 277 (2002), 5882–5890.
45. 45 Sorensen, P.H., et al. PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20 (2002), 2672–2679.
46. 46 Missiaglia, E., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 30 (2012), 1670–1677.
47. 47 Shaw, A.T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12, 1004-1012.
48. 48 Ren, S., et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 22 (2012), 806–821.
49. 49 Ren, G., et al. Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?. OMICS 18 (2014), 615–624.
50. 50 Nacu, S. et al. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genomics 4, 11.
51. 51 Mori, H., et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Nat. Acad. Sci. U.S.A. 99 (2002), 8242–8247.
52. 52 Biernaux, C., et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86 (1995), 3118–3122.
53. 53 Bose, S., et al. The presence of typical and atypical BCR–ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92 (1998), 3362–3367.
54. 54 Eguchi-Ishimae, M., et al. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. Blood 97 (2001), 737–743.
55. 55 Quina, A.S., et al. PML–RARA fusion transcripts in irradiated and normal hematopoietic cells. Genes, Chromosomes & Cancer 29 (2000), 266–275.
56. 56 Uckun, F.M., et al. Clinical significance of MLL–AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 92 (1998), 810–821.
57. 57 Jothi, M., et al. Small molecule inhibition of PAX3–FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol. Cancer Ther. 12 (2013), 2663–2674.
58. 58 Loupe, J.M., et al. Inhibiting phosphorylation of the oncogenic PAX3–FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis, 4, 2015, e145.
59. 59 Sibley, C.R., et al. Lessons from non-canonical splicing. Nat. Rev. Genet. 17 (2016), 407–421.
60. 60 Lopez-Bigas, N., et al. Are splicing mutations the most frequent cause of hereditary disease?. FEBS Lett. 579 (2005), 1900–1903.
61. 61 Singh, R.K., Cooper, T.A., Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 18 (2012), 472–482.
62. 62 Daguenet, E., et al. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep. 16 (2015), 1640–1655.
63. 63 Quesada, V., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44 (2012), 47–52.
64. 64 Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
65. 65 Biankin, A.V., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 (2012), 399–405.
66. 66 Yoshida, K., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478 (2011), 64–69.
67. 67 Berger, M.F., et al. The genomic complexity of primary human prostate cancer. Nature 470 (2011), 214–220.
68. 68 Cancer Genome Atlas Research, N., Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
69. 69 Stephens, P.J., et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462 (2009), 1005–1010.
70. 70 Rickman, D.S., et al. SLC45A3–ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 69 (2009), 2734–2738.
71. 71 Wen, H., et al. New fusion transcripts identified in normal karyotype acute myeloid leukemia. PloS ONE, 7, 2012, e51203.
72. 72 Taylor, B.S., Ladanyi, M., Clinical cancer genomics: how soon is now?. J. Pathol. 223 (2011), 318–326.
73. 73 Houseley, J., Tollervey, D., Apparent non-canonical trans-splicing is generated by reverse transcriptase in vitro. PLoS ONE, 5, 2010, e12271.
74. 74 McManus, C.J., et al. Regulatory divergence in Drosophila revealed by mRNA-seq. Genome Res. 20 (2010), 816–825.
75. 75 Liu, C., et al. FusionQ: a novel approach for gene fusion detection and quantification from paired-end RNA-Seq. BMC Bioinformatics, 14, 2013, 193.
76. 76 Kumar, S., et al. Comparative assessment of methods for the fusion transcripts detection from RNA-Seq data. Sci. Rep., 6, 2016, 21597.
77. 77 Zaphiropoulos, P.G., Trans-splicing in higher eukaryotes: Implications for cancer development?. Front Genet., 2, 2012, 92.
78. 78 Nowacki, M., et al. RNA-mediated epigenetic programming of a genome-rearrangement pathway. Nature 451 (2008), 153–158.
79. 79 Storici, F., et al. RNA-templated DNA repair. Nature 447 (2007), 338–341.
80. 80 Francia, S., et al. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 488 (2012), 231–235.
81. 81 Michalik, K.M., et al. A small RNA response at DNA ends in Drosophila. Nucleic Acids Res. 40 (2012), 9596–9603.
82. 82 Wei, W., et al. A role for small RNAs in DNA double-strand break repair. Cell 149 (2012), 101–112.
83. 83 Keskin, H., et al. Transcript-RNA-templated DNA recombination and repair. Nature 515 (2014), 436–439.